Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neuroblastoma DNA vaccine (Belarusian Research Center)
- Development stage
- Unknown
- Lead developer
- Belarusian Research Center for Pediatric Oncology Hematology and Immunology
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Oral
01
Overview
This experimental DNA vaccine, developed by the Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, is an investigational immunotherapy for relapsed neuroblastoma. The vaccine utilizes a dual-delivery platform: an intramuscular injection of a DNA-polyethylenimine (PEI) conjugate and an oral administration of an attenuated *Salmonella enterica* serovar typhimurium strain (SS2017) carrying the DNA plasmids. The vaccine constructs encode three neuroblastoma-associated antigens—tyrosine hydroxylase (TH), PHOX2B, and survivin—each fused to the potato virus X coat protein (PVXCP) to enhance the immune response. This strategy is designed to overcome immune tolerance and stimulate a robust T-cell response against tumor cells. It is currently being evaluated in a pilot clinical trial (NCT04049864) to assess safety and immunogenicity in pediatric patients.
- Other names
- DNA vaccine against neuroblastomaDNA-polyethylenimine conjugateSalmonella oral vaccine
02
Targets
TH (Tyrosine hydroxylase)BIRC5 (Survivin)PHOX2B (Paired-like homeobox 2b protein)
Beyond the preview
Go deeper on Neuroblastoma DNA vaccine (Belarusian Research Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuroblastoma DNA vaccine (Belarusian Research Center).